| Basics |
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
|
| IPO Date: |
May 1, 2012 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$2.62B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.47 | 1.99%
|
| Avg Daily Range (30 D): |
$0.75 | 1.54%
|
| Avg Daily Range (90 D): |
$0.66 | 1.47%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.48M |
| Avg Daily Volume (30 D): |
.81M |
| Avg Daily Volume (90 D): |
.71M |
| Trade Size |
| Avg Trade Size (Sh.): |
88 |
| Avg Trade Size (Sh.) (30 D): |
49 |
| Avg Trade Size (Sh.) (90 D): |
49 |
| Institutional Trades |
| Total Inst.Trades: |
4,496 |
| Avg Inst. Trade: |
$1.73M |
| Avg Inst. Trade (30 D): |
$3.44M |
| Avg Inst. Trade (90 D): |
$3.15M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.09M |
| Avg Closing Trade (30 D): |
$5.68M |
| Avg Closing Trade (90 D): |
$5.37M |
| Avg Closing Volume: |
65.93K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.33
|
$-.8
|
$.4
|
|
Diluted EPS
|
$-.34
|
$-.8
|
$.4
|
|
Revenue
|
$ 681.54M
|
$ 192.1M
|
$ 165.45M
|
|
Gross Profit
|
$ 603.89M
|
$ 173.14M
|
$ 148.63M
|
|
Net Income / Loss
|
$ -19.12M
|
$ -45.12M
|
$ 22.5M
|
|
Operating Income / Loss
|
$ -36.94M
|
$ -60.23M
|
$ 12.14M
|
|
Cost of Revenue
|
$ 77.65M
|
$ 18.97M
|
$ 16.83M
|
|
Net Cash Flow
|
$ 121.15M
|
$ 8.11M
|
$ 28.86M
|
|
PE Ratio
|
|
|
|
|
|
|
